Saturday 17 October 2026
Export VRDN’s income statement to Excel — free account
Viridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024. In the quarter to June 2026, revenue grew 278.7%, EPS fell 5.00%, free cash flow fell 41.4% and total debt rose 1,064.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.03
0.53
−2.71%
Follow VRDN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 4 | 2 | 3 | 4 | 2 | 2 | 3 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.91 | 49.59 | 10.70 | 3.37 | 30.32 | 79.53 | 516.07 | 3,185.59 | 4,309.19 | 37.25 |
Altman Z-Score |
(4.90) | 5.63 | 0.50 | (10.81) | (1.52) | 6.20 | 12.56 | 9.42 | 8.94 | 6.69 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(7.31) | (0.32) | (0.13) | (22.06) | 4.60 | 9.97 | 10.63 | 7.43 | 8.99 | 2.72 |
P/Operating CF |
(0.96) | (27.41) | (10.98) | (1.93) | (6.20) | (14.25) | (26.86) | (26.32) | (17.75) | (111.10) |
Beneish M-Score |
(1.13) | 54.73 | (2.77) | — | — | — | — | — | — | — |
P/B ratio |
0.00 | 5.15 | 1.75 | 0.95 | 0.00 | 4.37 | 3.62 | 4.25 | 2.70 | 4.47 |
Price to Tangible BV |
0.00 | 5.15 | 1.75 | 0.95 | 0.00 | 4.37 | 3.62 | 4.25 | 2.70 | 4.47 |
EV/Sales |
(4.62) | 40.71 | 4.44 | (0.78) | (35.56) | 13.40 | 279.45 | 1,732.26 | 2,003.95 | 25.73 |
EV/EBITDA |
0.96 | 0.00 | 0.00 | 0.08 | 0.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
1.09 | (5.79) | (1.39) | 0.10 | 2.30 | (0.73) | (5.28) | (2.95) | (2.60) | (6.59) |
EV/FCF |
1.07 | (5.74) | (1.36) | 0.10 | 2.30 | (0.72) | (5.23) | (2.94) | (2.60) | (6.58) |
Quick Ratio |
3.21 | 12.55 | 9.28 | 2.64 | 11.96 | 14.44 | 12.73 | 17.92 | 14.99 | 12.37 |
Current Ratio |
3.47 | 13.31 | 9.71 | 2.92 | 12.14 | 14.68 | 12.93 | 18.26 | 15.43 | 12.65 |
Net Debt/EBITDA |
1.16 | 1.43 | 1.64 | 0.53 | 1.16 | 2.50 | 3.13 | 1.72 | 2.22 | 2.23 |
Debt/Assets |
11.39% | 18.91% | 12.10% | 14.30% | 0.03% | 0.26% | 1.07% | 4.12% | 2.77% | 5.55% |
Debt/Equity |
0.19 | 0.26 | 0.16 | 0.27 | 0.00 | 0.00 | 0.01 | 0.05 | 0.03 | 0.07 |
Asset Turnover |
0.18 | 0.10 | 0.14 | 0.09 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.09 |
Operating CF/Net income |
0.85 | 1.06 | 0.82 | 0.86 | 0.27 | 0.69 | 0.72 | 0.77 | 0.86 | 0.81 |
Capex/Depreciation |
(0.73) | (0.80) | 3.30 | 0.58 | (0.07) | (0.24) | (17.71) | 0.08 | 0.03 | 0.08 |
Interest Coverage |
(52.11) | (69.27) | (37.90) | (50.27) | (217.28) | (26,576.00) | (276.35) | (191.17) | (136.11) | (73.44) |
| 67.26% | 226.53% | (72.79%) | (124.81%) | 491.96% | 2,308.18% | (84.66%) | (97.35%) | (75.17%) | (63.87%) | |
| (91.99%) | (68.66%) | (55.14%) | (86.87%) | (137.09%) | (47.42%) | (40.66%) | (51.37%) | (43.79%) | (41.73%) | |
ROIC |
0.00% | (1,673.31%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(98.33%) | (54.64%) | (55.09%) | (208.51%) | (92.85%) | (42.49%) | (32.54%) | (51.51%) | (39.02%) | (41.54%) |
Average Days of Receivables |
2.10 | 132.76 | 1.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
393.79% | 490.21% | 362.76% | 779.96% | 9,349.05% | 1,919.88% | 5,693.79% | 50,880.57% | 78,892.05% | 478.38% |
Selling, General and Administrative Expense of Revenue |
194.77% | 272.60% | 131.76% | 261.06% | 1,263.33% | 870.91% | 1,985.44% | 30,254.46% | 20,226.16% | 134.53% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
5.69% | 60.18% | 43.87% | 88.99% | 347.14% | 488.19% | 1,115.41% | 21,392.36% | 13,956.95% | 62.53% |
Graham Net Nets |
4.47 | 0.19 | 0.56 | 1.01 | 2.02 | 0.78 | 0.43 | 0.44 | 0.51 | 0.27 |
Graham Number |
3,642.15 | 0.00 | 0.00 | 0.00 | 105.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(505.34%) | (14.54%) | (35.96%) | (279.03%) | (176.70%) | (38.90%) | (14.14%) | (23.80%) | (20.71%) | (10.57%) |
Free Cash Flow Yield |
(473.75%) | (14.31%) | (30.41%) | (240.28%) | (50.97%) | (23.27%) | (10.35%) | (18.50%) | (17.89%) | (10.49%) |
Revenue per Share |
84.80 | 3.12 | 4.25 | 2.14 | 0.30 | 0.25 | 0.06 | 0.01 | 0.00 | 0.84 |
Operating CF per Share |
(359.88) | (21.94) | (13.60) | (17.26) | (8.37) | (4.58) | (2.92) | (4.12) | (3.42) | (3.26) |
Capex per Share |
(6.10) | (0.19) | (0.23) | (0.04) | (0.01) | (0.02) | (0.02) | (0.02) | (0.01) | (0.01) |
Free Cash Flow per Share |
(365.98) | (22.14) | (13.82) | (17.30) | (8.38) | (4.60) | (2.95) | (4.14) | (3.43) | (3.26) |
Cash per Share |
539.12 | 36.96 | 31.65 | 12.85 | 35.88 | 16.53 | 13.23 | 10.67 | 10.57 | 10.31 |
Shareholders Equity per Share |
367.20 | 30.00 | 26.01 | 7.54 | 33.75 | 15.75 | 12.31 | 9.88 | 9.89 | 8.52 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
367.20 | 30.00 | 26.01 | 7.54 | 33.75 | 15.75 | 12.31 | 9.88 | 9.89 | 8.52 |
Free Cash Flow |
(15.00) | (28.41) | (27.29) | (36.14) | (29.82) | (54.84) | (94.63) | (185.07) | (232.83) | (276.89) |
Working Capital |
16.99 | 47.97 | 58.64 | 19.56 | 118.94 | 186.53 | 397.82 | 459.84 | 690.59 | 823.54 |
Capital Expenditures |
(0.25) | (0.25) | (0.44) | (0.08) | (0.04) | (0.26) | (0.80) | (0.90) | (0.51) | (0.49) |
Net Current Asset Value |
14.17 | 37.90 | 50.57 | 15.23 | 118.39 | 184.17 | 391.15 | 438.08 | 667.70 | 716.98 |
EV/EBIT |
0.95 | 0.00 | 0.00 | 0.08 | 0.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.07 | 0.06 | 0.05 | 0.02 | 0.04 | 0.09 | 0.45 | 2.86 | 1.69 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.55 | 0.55 | (0.19) | (0.28) | 1.86 | 2.89 | 0.03 | (6.56) | (12.23) | (5.13) |
Cash ROIC |
(37.53%) | (29.64%) | (22.40%) | (77.01%) | (12.04%) | (14.24%) | (11.48%) | (19.70%) | (16.52%) | (16.81%) |
Accounts Receivable Turnover |
16.80 | 5.42 | 11.33 | 67.59 | 0.00 | 10.60 | 6.41 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.21 | 0.74 | 0.74 | 0.07 | — | 0.28 | 0.28 | — | — | — |
Average Payables |
0.62 | 0.96 | 0.74 | 0.83 | 0.88 | 1.50 | 8.28 | 8.24 | 2.19 | 5.41 |
Average Assets |
18.83 | 38.62 | 59.31 | 48.20 | 80.76 | 167.48 | 319.40 | 462.76 | 616.41 | 820.91 |
Average Common Equity |
(25.76) | (11.71) | 44.93 | 33.55 | (22.50) | (3.44) | 153.40 | 244.21 | 359.13 | 536.43 |
Columns are period end dates